



TECH CENTER 1600/2900

FEB 14 2002

RECEIVED

PATENT

Docket No. 10806-106

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, DC 20231 on January 7, 2002.

[Signature]

#12/C
(~~12~~)
JRP
2/26/02

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: Johan Stjernschantz et al : Paper No.:
Serial No.: 09/445,919 : Group Art Unit: 1614
Filed: March 16, 2000 : Examiner: Z. Fay
For: **Prostaglandin Derivatives Devoid of Side-Effects for the Treatment of Glaucoma**

AMENDMENT UNDER 37 C.F.R. 1.116

Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Concurrent with the filing of an Appeal Brief, Applicants request amendment of the present application as follows:

In the Claims:

Please cancel claims 1-3 and 13-17.

Please amend claims 4, 5 and 18-21 to read as follows:

4. (Twice Amended) A composition for the treatment of glaucoma and ocular hypertension comprising a therapeutically active and physiologically acceptable amount of a prostaglandin analogue which is a selective agonist for EP₁ prostanoid receptors, or a pharmaceutically acceptable salt or ester thereof, wherein the prostaglandin analogue is 15(R,S)-16,16-trimethylene-PGE₂ or an alkyl ester thereof.